SLE
MCID: SYS001
MIFTS: 86

Systemic Lupus Erythematosus (SLE) malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus

Aliases & Descriptions for Systemic Lupus Erythematosus:

Name: Systemic Lupus Erythematosus 54 38 12 25 51 66 3 14
Lupus Nephritis 54 12 50 52 42 14 69
Lupus Erythematosus, Systemic 12 29 42 69
Disseminated Lupus Erythematosus 12 25
Libman-Sacks Disease 25 69
Sle 25 66
Sle - Lupus Erythematosus, Systemic 12
Lupus Erythematosus Systemic 52
Lupus Erythematosus, Discoid 69
Lupus Erythematosus 69
Lupus Vulgaris 69
Le Syndrome 25
Lupus 25

Characteristics:

HPO:

32
systemic lupus erythematosus:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 152700
Disease Ontology 12 DOID:0080162 DOID:9074
ICD10 33 M32 M32.9 M32.1
ICD9CM 35 710.0
NCIt 47 C3201
UMLS 69 C0024141

Summaries for Systemic Lupus Erythematosus

OMIM : 54 Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by production of autoantibodies... (152700) more...

MalaCards based summary : Systemic Lupus Erythematosus, also known as lupus nephritis, is related to systemic lupus erythematosus 1 and tuberculosis, and has symptoms including seizures, arthritis and hemolytic anemia. An important gene associated with Systemic Lupus Erythematosus is PTPN22 (Protein Tyrosine Phosphatase, Non-Receptor Type 22), and among its related pathways/superpathways are Systemic lupus erythematosus and Innate Immune System. The drugs Simvastatin and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, t cells and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Disease Ontology : 12 A lupus erythematosus that is an inflammation of connective tissue marked by skin rashes, joint pain and swelling, inflammation of the kidneys and inflammation of the tissue surrounding the heart.

Genetics Home Reference : 25 Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. The signs and symptoms of SLE vary among affected individuals, and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system. SLE is one of a large group of conditions called autoimmune disorders that occur when the immune system attacks the body's own tissues and organs.

NIH Rare Diseases : 50 lupus nephritis is a kidney disorder that is a complication of systemic lupus erythematous (sle), commonly known as lupus. the symptoms of lupus nephritis include blood in the urine, a foamy appearance to the urine, high blood pressure, and swelling in any part of the body. this condition typically occurs in people aged 20 to 40 years. treatment may involve medications to suppress the immune system, dialysis, or a kidney transplant. visit our web page on lupus for more information and resources. last updated: 11/24/2010

CDC : 3 Lupus occurs when an unknown trigger causes a person’s own immune system to attack their tissues, damaging the tissues and producing widespread inflammation. There is no known cause or cure for lupus; however, treatments are available.

NINDS : 51 Lupus (also called ) is a disorder of the immune system. Normally, the immune system protects the body against invading infections and cancers. In lupus, the immune system is over-active and produces increased amounts of abnormal antibodies that attack the body's tissues and organs. Lupus can affect many parts of the body, including the joints, skin, kidneys, lungs, heart, nervous system, and blood vessels. The signs and symptoms of lupus differ from person to person; the disease can range from mild to life threatening.

UniProtKB/Swiss-Prot : 66 Systemic lupus erythematosus: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Wikipedia : 71 Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the... more...

Related Diseases for Systemic Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 1
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 16 Systemic Lupus Erythematosus 3
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 12 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 7
Systemic Lupus Erythematosus 8 Cr2-Related Susceptibility to Systemic Lupus Erythematosus
Dnase1-Related Susceptibility to Systemic Lupus Erythematosus Itgam-Related Susceptibility to Systemic Lupus Erythematosus

Diseases related to Systemic Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 773)
id Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 1 34.4 CD40LG TLR5 TLR9
2 tuberculosis 31.0 CD40LG IL10 TLR9
3 b-cell lymphomas 30.6 CD40LG CTLA4 PDCD1
4 membranoproliferative glomerulonephritis 30.4 APOH CD40LG IL10 TLR9 TRIM21
5 melioidosis 30.1 TLR5 TREX1
6 stiff-person syndrome 30.1 APOH CD40LG PTPN22
7 asbestosis 30.1 APOH FCGR2A IL10
8 systemic lupus erythematosus 16 12.6
9 systemic lupus erythematosus 2 12.5
10 systemic lupus erythematosus 9 12.4
11 systemic lupus erythematosus 10 12.4
12 pediatric systemic lupus erythematosus 12.3
13 systemic lupus erythematosus 11 12.3
14 systemic lupus erythematosus 3 12.2
15 systemic lupus erythematosus 12 12.2
16 systemic lupus erythematosus 4 12.2
17 lupus erythematosus 12.2
18 systemic lupus erythematosus 5 12.1
19 systemic lupus erythematosus with nephritis 1 12.1
20 systemic lupus erythematosus with nephritis 3 12.1
21 neonatal systemic lupus erythematosus 12.1
22 systemic lupus erythematosus with nephritis 2 12.1
23 systemic lupus erythematosus 14 12.1
24 systemic lupus erythematosus 13 12.1
25 systemic lupus erythematosus 7 12.1
26 systemic lupus erythematosus 8 12.1
27 cr2-related susceptibility to systemic lupus erythematosus 12.0
28 dnase1-related susceptibility to systemic lupus erythematosus 12.0
29 itgam-related susceptibility to systemic lupus erythematosus 12.0
30 neonatal lupus erythematosus 12.0
31 systemic lupus erythematous, association with 6 11.7
32 vitiligo-associated multiple autoimmune disease susceptibility 1 11.6
33 c1q deficiency 11.6
34 mixed connective tissue disease 11.5
35 pure red-cell aplasia 11.3
36 drug-induced lupus erythematosus 11.3
37 sjogren's syndrome 11.3
38 epidermolysis bullosa acquisita 11.3
39 macrophage activation syndrome 11.3
40 collagen disease 11.3
41 undifferentiated connective tissue disease 11.3
42 rapidly progressive glomerulonephritis 11.3
43 lupus erythematosus tumidus 11.3
44 c1s deficiency 11.3
45 c3 deficiency 11.3
46 sneddon syndrome 11.3
47 autoimmune inner ear disease 11.0
48 c2 deficiency 11.0
49 c1q nephropathy 11.0
50 mikulicz disease 11.0

Comorbidity relations with Systemic Lupus Erythematosus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Mitral Valve Disease Neutropenia
Osteoporosis Postinflammatory Pulmonary Fibrosis
Raynaud Disease Rheumatoid Arthritis
Sjogren's Syndrome Systemic Scleroderma

Graphical network of the top 20 diseases related to Systemic Lupus Erythematosus:



Diseases related to Systemic Lupus Erythematosus

Symptoms & Phenotypes for Systemic Lupus Erythematosus

Symptoms by clinical synopsis from OMIM:

152700

Clinical features from OMIM:

152700

Human phenotypes related to Systemic Lupus Erythematosus:

32 (show all 13)
id Description HPO Frequency HPO Source Accession
1 seizures 32 HP:0001250
2 arthritis 32 HP:0001369
3 hemolytic anemia 32 HP:0001878
4 thrombocytopenia 32 HP:0001873
5 psychosis 32 HP:0000709
6 pericarditis 32 HP:0001701
7 cutaneous photosensitivity 32 HP:0000992
8 leukopenia 32 HP:0001882
9 pleuritis 32 HP:0002102
10 systemic lupus erythematosus 32 HP:0002725
11 antinuclear antibody positivity 32 HP:0003493
12 antiphospholipid antibody positivity 32 HP:0003613
13 nephritis 32 HP:0000123

UMLS symptoms related to Systemic Lupus Erythematosus:


cyanosis, exanthema, icterus, pruritus, lupus-like rash, seizures

GenomeRNAi Phenotypes related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.81 C4A C4B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.81 C4A C4B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.81 APOH
4 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.81 FCGR2B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.81 FCGR2B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.81 C4A C4B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.81 FCGR2B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.81 FCGR2B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.81 C4A C4B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.81 C4A C4B
11 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.81 PDCD1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.81 PDCD1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.81 C4A C4B
14 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.81 PDCD1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.81 APOH C4A C4B FCGR2B PDCD1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.81 FCGR2B
17 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.81 APOH
18 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.81 FCGR2B
19 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.81 C4A C4B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.81 APOH

MGI Mouse Phenotypes related to Systemic Lupus Erythematosus:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 PDCD1 PTPN22 SSB TLR5 TLR9 TREX1
2 immune system MP:0005387 10.2 C4B CD40LG CTLA4 DNASE1 FCGR2A FCGR2B
3 homeostasis/metabolism MP:0005376 10.18 TRIM21 APOH C4B CD40LG CTLA4 DNASE1
4 cardiovascular system MP:0005385 10.11 C4B CD40LG CTLA4 FCGR2B IL10 PDCD1
5 mortality/aging MP:0010768 10.06 APOH C4B CD40LG CTLA4 DNASE1 FCGR2A
6 digestive/alimentary MP:0005381 10.03 C4B CTLA4 FCGR2B IL10 PTPN22 TLR5
7 liver/biliary system MP:0005370 9.86 C4B CTLA4 FCGR2B IL10 PDCD1 PTPN22
8 renal/urinary system MP:0005367 9.65 PTPN22 TLR9 TREX1 TRIM21 TROVE2 C4B
9 respiratory system MP:0005388 9.17 CTLA4 FCGR2B IL10 PDCD1 PTPN22 TLR5

Drugs & Therapeutics for Systemic Lupus Erythematosus

Drugs for Systemic Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 376)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
9
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
10
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
11
Benzocaine Approved Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
12
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
13
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
14
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2 118-42-3 3652
15
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
16
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
17
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
18
Cilostazol Approved Phase 4 73963-72-1 2754
19
Lenalidomide Approved Phase 4 191732-72-6 216326
20
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 124-94-7 31307
21
Metformin Approved Phase 4 657-24-9 14219 4091
22
Sulfamethoxazole Approved Phase 4 723-46-6 5329
23
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
24
Thioguanine Approved Phase 4 154-42-7 2723601
25
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
26
Bortezomib Approved, Investigational Phase 4,Phase 2 179324-69-7 387447 93860
27 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1
28
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 134070 5280453
29
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
31
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 54575, 6560146 143
32
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
33 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Rosuvastatin Calcium Phase 4,Phase 2,Phase 1 147098-20-2
40 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
43 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
44 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
48 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
50 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 622)
id Name Status NCT ID Phase
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4
3 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4
6 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4
7 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
8 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4
9 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4
10 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4
11 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4
12 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4
13 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4
14 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4
15 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4
16 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4
17 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4
18 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4
19 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4
20 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4
21 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4
22 Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4
23 Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis Completed NCT01203709 Phase 4
24 Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis Completed NCT02645565 Phase 4
25 Mycophenolate Mofetil for IgA Nephropathy Completed NCT00863252 Phase 4
26 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Recruiting NCT01632241 Phase 4
27 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4
28 The Effect of Metformin on Reducing Lupus Flares Recruiting NCT02741960 Phase 4
29 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4
30 Belimumab Assessment of Safety in SLE Recruiting NCT01705977 Phase 4
31 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4
32 Safety and Immunogenicity of a Zoster Vaccine in SLE Recruiting NCT02477150 Phase 4
33 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Recruiting NCT03098823 Phase 4
34 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
35 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4
36 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4
37 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4
38 Thiopurine Induced Pancreatitis in IBD Patients Recruiting NCT02281799 Phase 4
39 Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis Recruiting NCT02630628 Phase 4
40 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Recruiting NCT02765594 Phase 4
41 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4
42 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Not yet recruiting NCT03122431 Phase 4
43 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4
44 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
45 A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients Terminated NCT01316133 Phase 4
46 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4
47 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4
48 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4
49 Velcade for Proliferative Lupus Nephritis Withdrawn NCT01169857 Phase 4
50 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3

Search NIH Clinical Center for Systemic Lupus Erythematosus

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Systemic Lupus Erythematosus cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lupus nephritis

Genetic Tests for Systemic Lupus Erythematosus

Genetic tests related to Systemic Lupus Erythematosus:

id Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 29

Anatomical Context for Systemic Lupus Erythematosus

MalaCards organs/tissues related to Systemic Lupus Erythematosus:

39
T Cells, Kidney, Skin, B Cells, Heart, Lung, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Systemic Lupus Erythematosus:
id Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Systemic Lupus Erythematosus

Articles related to Systemic Lupus Erythematosus:

(show top 50) (show all 5142)
id Title Authors Year
1
Bone Marrow Involvement in Systemic Lupus Erythematosus. ( 28525589 )
2017
2
Case of Pediatric Bullous Systemic Lupus Erythematosus Treated with Intravenous Immunoglobulin. ( 27778386 )
2017
3
The association between systemic lupus erythematosus and bipolar disorderA -A a big data analysis. ( 28525775 )
2017
4
The relevance of cluster analyses to stratify systemic lupus erythematosus: increased mortality with heavier treatment. ( 28516870 )
2017
5
Tjalma syndrome (pseudo-pseudo Meigs') as initial manifestation of juvenile-onset systemic lupus erythematosus. ( 28522234 )
2017
6
Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus. ( 27981461 )
2017
7
Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus Erythematosus Identified Hypomethylation in Genes Related to the Type I Interferon Pathway. ( 28085900 )
2017
8
Analysis of the CD161-expressing cell quantities and CD161 expression levels in peripheral blood natural killer and T cells of systemic lupus erythematosus patients. ( 26590595 )
2017
9
Lymphadenopathy syndrome in systemic lupus erythematosus: Is it Kikuchi-Fujimoto disease? ( 27375282 )
2017
10
Pulse dose steroids in severe pulmonary arterial hypertension secondary to systemic lupus erythematosus. ( 28515936 )
2017
11
Cerebral Venous Sinus Thrombosis Presenting Feature of Systemic Lupus Erythematosus. ( 28065614 )
2017
12
Identification of long non-coding RNAs GAS5, linc0597 and lnc-DC in plasma as novel biomarkers for systemic lupus erythematosus. ( 28423570 )
2017
13
25-Hydroxivitamin D Serum Concentration, Not Free and Bioavailable Vitamin D, Is Associated with Disease Activity in Systemic Lupus Erythematosus Patients. ( 28085957 )
2017
14
Socioeconomic consequences of systemic lupus erythematosus. ( 28520683 )
2017
15
Associations between PTPN22 and TLR9 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis. ( 28528372 )
2017
16
Association between circulating transforming growth factor-I^1 level and polymorphisms in systemic lupus erythematosus and rheumatoid arthritis: A meta-analysis. ( 28234629 )
2017
17
Association of IRF5 polymorphisms with increased risk for systemic lupus erythematosus in population of Crete, a southern-eastern European Greek island. ( 28185859 )
2017
18
Spatial Working Memory Impairment in Patients with Non-neuropsychiatric Systemic Lupus Erythematosus: A Blood-oxygen-level Dependent Functional Magnetic Resonance Imaging Study. ( 28089970 )
2017
19
Uveitis in childhood-onset systemic lupus erythematosus patients: a multicenter survey. ( 28070763 )
2017
20
Effects of 1,25(OH)2 D3 and vitamin D receptor on peripheral CD4(+) /CD8(+) double-positive T lymphocytes in a mouse model of systemic lupus erythematosus. ( 28063200 )
2017
21
Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. ( 28534427 )
2017
22
Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX: Clinical Features and Survival of Childhood-Onset Systemic Lupus Erythematosus in China. ( 28524825 )
2017
23
Unraveling the expression of microRNA-27a* & NKG2D in peripheral blood mononuclear cells and natural killer cells of pediatric systemic lupus erythematosus patients. ( 28523761 )
2017
24
Medication Non-Adherence in Systemic Lupus Erythematosus: A Systematic Review. ( 28086003 )
2017
25
A Case Report of Widespread Majocchi's Granuloma in a Patient with Systemic Lupus Erythematosus. ( 28083794 )
2017
26
Elevated semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis. ( 28063160 )
2017
27
Anti-C1q Antibody is Associated with Renal and Cutaneous Manifestations in Asian Indian Patients with Systemic Lupus Erythematosus. ( 28511434 )
2017
28
Association Between TNF-I+ Promoter -308 A/G Polymorphism and Systemic Lupus Erythematosus Susceptibility: A Case-Control Study and Meta-Analysis. ( 27943420 )
2017
29
Alterations of white matter structural networks in patients with non-neuropsychiatric systemic lupus erythematosus identified by probabilistic tractography and connectivity-based analyses. ( 28066709 )
2017
30
Cardiac tamponade as an initial presentation for systemic lupus erythematosus. ( 28526593 )
2017
31
Genetic advances in systemic lupus erythematosus: an update. ( 28509669 )
2017
32
Acquired hemophilia as initial presentation in a patient with Systemic Lupus Erythematosus. ( 28523993 )
2017
33
Angiotensin type 1 receptor A1166C polymorphism and systemic lupus erythematosus: correlation with cellular immunity and oxidative stress markers. ( 28530466 )
2017
34
Atypical Trigeminal Neuralgia: A Rare Neurological Manifestation of Systemic Lupus Erythematosus. ( 28077839 )
2017
35
Pneumococcal infection in patients with systemic lupus erythematosus. ( 28529115 )
2017
36
Acute necrotizing retinal vasculitis as onset of systemic lupus erythematosus: A case report. ( 28079801 )
2017
37
Gastrointestinal system involvement in systemic lupus erythematosus. ( 28523968 )
2017
38
Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study. ( 28091805 )
2017
39
SLAMF7 engagement restores defective effector CD8+ T cells activity in response to foreign antigens in systemic lupus erythematosus. ( 28076903 )
2017
40
Association of aortic perivascular adipose tissue density with aortic calcification in women with systemic lupus erythematosus. ( 28521185 )
2017
41
Mycobacterium avium Complex Septic Arthritis Presenting as Osteonecrosis of the Femoral Head in a Patient With Systemic Lupus Erythematosus. ( 28056158 )
2017
42
Atypical bone change of spine caused by epidural venous thrombosis in systemic lupus erythematosus with antiphospholipid syndrome. ( 28063414 )
2017
43
Multifocal Osteonecrosis in an Adolescent Patient With Systemic Lupus Erythematosus and Ankle Pain. ( 28002155 )
2017
44
Osteoporotic fractures in patients with systemic lupus erythematosus and end stage renal disease. ( 28530467 )
2017
45
In Vitro Fertilization in 37 Women with Systemic Lupus Erythematosus or Antiphospholipid Syndrome: A Series of 97 Procedures. ( 28089975 )
2017
46
Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap. ( 28089979 )
2017
47
DUSP23 is over-expressed and linked to the expression of DNMTs in CD4(+) T cells from systemic lupus erythematosus patients. ( 27737517 )
2017
48
Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab. ( 26385220 )
2016
49
Association of CTLA4 exon-1 polymorphism with the tumor necrosis factor-I+ in the risk of systemic lupus erythematosus among South Indians. ( 26582004 )
2016
50
PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus. ( 26867643 )
2016

Variations for Systemic Lupus Erythematosus

UniProtKB/Swiss-Prot genetic disease variations for Systemic Lupus Erythematosus:

66
id Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601
2 TREX1 p.Arg169His VAR_028319 rs72556554
3 TREX1 p.Ala213Val VAR_037949 rs762011967
4 TREX1 p.Gly282Ser VAR_037950 rs113107733
5 TREX1 p.Arg295Ser VAR_037951 rs72556555
6 TREX1 p.Ala302Pro VAR_037952 rs112741962
7 TREX1 p.Pro345Leu VAR_037954 rs148833270
8 TREX1 p.Tyr360Cys VAR_037955 rs370504038
9 TREX1 p.Gly361Ala VAR_037956 rs780022923
10 TREX1 p.Asp255His VAR_070901

ClinVar genetic disease variations for Systemic Lupus Erythematosus:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TREX1 NM_033629.4(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh37 Chromosome 3, 48508395: 48508395

Copy number variations for Systemic Lupus Erythematosus from CNVD:

7 (show all 43)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14694 1 110000000 163800000 Gain or loss FCGR3B Systemic lupus erythematosus
2 21050 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
3 21051 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
4 21053 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
5 21628 1 159859611 159867782 Copy number FCGR3B Systemic lupus erythematosus
6 21630 1 159859611 159867782 Low copy number FCGR3B Systemic lupus erythematosus
7 21794 1 161592989 161601158 Copy number FCGR3B Systemic lupus erythematosus
8 21797 1 161592989 161601158 Deletion FCGR3B Systemic lupus erythematosus
9 107133 17 1225928 31649829 Copy number CCL3L3 Systemic lupus erythematosus
10 107143 17 1225928 31649843 Copy number CCL3L1 Systemic lupus erythematosus
11 107163 17 1242109 31665953 Copy number CCL4L2 Systemic lupus erythematosus
12 110232 17 31562580 31665959 Copy number CCL4L1 Systemic lupus erythematosus
13 110282 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
14 110283 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
15 110288 17 31800000 38100000 Copy number CCL4L1 Systemic lupus erythematosus
16 112168 17 38100000 38400000 Copy number CCL3L1 Systemic lupus erythematosus
17 113342 17 43165608 43178484 Amplification T-bet Systemic lupus erythematosus
18 162470 22 21800000 24300000 Gain or loss GSTT1 Systemic lupus erythematosus
19 186012 4 2713184 2727859 Deletion TNIP2 Systemic lupus erythematosus
20 196060 5 158674368 158690059 Amplification IL-12B Systemic lupus erythematosus
21 204042 6 105500000 114600000 Copy number C4A Systemic lupus erythematosus
22 204043 6 105500000 114600000 Copy number C4B Systemic lupus erythematosus
23 207132 6 15200000 46200000 Copy number Systemic lupus erythematosus
24 209409 6 2614953 31491069 Copy number MICA Systemic lupus erythematosus
25 210235 6 29900000 36800000 Low copy numbers C4 Systemic lupus erythematosus
26 210494 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
27 210495 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
28 210499 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
29 210506 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
30 210507 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
31 210512 6 30400000 36600000 Gain C4A Systemic lupus erythematosus
32 210513 6 30400000 36600000 Gain C4B Systemic lupus erythematosus
33 211033 6 31949833 32003194 Copy number C4A Systemic lupus erythematosus
34 211045 6 3197570 32111174 Copy number C4A Systemic lupus erythematosus
35 211049 6 3197570 32111174 Duplication C4 Systemic lupus erythematosus
36 211054 6 31982571 32003194 Copy number C4B Systemic lupus erythematosus
37 211360 6 32593131 32665540 Copy number HLA-DRB5 Systemic lupus erythematosus
38 212285 6 3674895 32665540 Copy number HLA-DRB1 Systemic lupus erythematosus
39 212431 6 3795995 32719407 Copy number HLA-DQA1 Systemic lupus erythematosus
40 212452 6 3813334 32742444 Copy number HLA-DQB1 Systemic lupus erythematosus
41 212671 6 40500000 46200000 Copy number Systemic lupus erythematosus
42 212678 6 40500000 93100000 Copy number Systemic lupus erythematosus
43 243031 8 7752198 7754236 Copy number DEFB4 Systemic lupus erythematosus

Expression for Systemic Lupus Erythematosus

LifeMap Discovery
Genes differentially expressed in tissues of Systemic Lupus Erythematosus patients vs. healthy controls: 35 (show all 12)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 5.47 0.000
2 OTOF otoferlin Blood + 5.25 0.000
3 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood - 4.40 0.000
4 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Blood + 4.22 0.000
5 LINC00661 long intergenic non-protein coding RNA 661 Blood + 4.15 0.000
6 SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin Blood + 4.12 0.000
7 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood - 3.96 0.000
8 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.81 0.000
9 IFI44L interferon-induced protein 44-like Blood + 3.58 0.000
10 USP41 ubiquitin specific peptidase 41 Blood + 3.40 0.000
11 HESX1 HESX homeobox 1 Blood + 3.22 0.000
12 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Blood + 3.08 0.000
Search GEO for disease gene expression data for Systemic Lupus Erythematosus.

Pathways for Systemic Lupus Erythematosus

Pathways related to Systemic Lupus Erythematosus according to KEGG:

37
id Name Kegg Source Accession
1 Systemic lupus erythematosus hsa05322

Pathways related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 C4A C4B CD40LG CR1 CTLA4 FCGR2A
2
Show member pathways
13.61 C4A C4B CD40LG FCGR2A FCGR3A IL10
3 12.34 CD40LG CTLA4 IL10 PDCD1 PTPN22 TLR9
4
Show member pathways
12.24 CD40LG CTLA4 IL10 PDCD1
5
Show member pathways
12.07 CD40LG CR1 FCGR2A FCGR3A IL10
6 11.89 CR1 FCGR2A FCGR2B FCGR3A IL10 TLR9
7
Show member pathways
11.76 IL10 TLR5 TLR9
8
Show member pathways
11.75 C4A C4B CR1
9 11.67 FCGR2A FCGR2B FCGR3A
10 11.66 CR1 FCGR2A TLR5 TLR9
11 11.57 C4A C4B IL10
12 11.42 CD40LG CTLA4 PDCD1
13 11.36 CD40LG IL10 PDCD1
14 11.31 CD40LG CR1 IL10 TLR9
15 11.18 C4A C4B FCGR2A FCGR2B FCGR3A IL10
16 11.17 CD40LG CR1 CTLA4 FCGR2A FCGR2B FCGR3A

GO Terms for Systemic Lupus Erythematosus

Cellular components related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD40LG CTLA4 FCGR3A PDCD1

Biological processes related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.88 CD40LG CTLA4 FCGR2B FCGR3A IL10
2 regulation of complement activation GO:0030449 9.71 C4A C4B CR1
3 innate immune response GO:0045087 9.63 C4A C4B CR1 TLR5 TLR9 TRIM21
4 T cell costimulation GO:0031295 9.58 CD40LG CTLA4 PDCD1
5 regulation of type I interferon production GO:0032479 9.52 TREX1 TRIM21
6 negative regulation of B cell proliferation GO:0030889 9.51 CTLA4 IL10
7 response to molecule of bacterial origin GO:0002237 9.49 IL10 TLR9
8 regulation of cytokine secretion GO:0050707 9.46 TLR5 TLR9
9 histone mRNA metabolic process GO:0008334 9.43 SNRPB SSB
10 inflammatory response GO:0006954 9.43 C4A C4B CD40LG IL10 TLR5 TLR9
11 positive regulation of apoptotic cell clearance GO:2000427 9.37 C4A C4B
12 negative regulation of interleukin-8 production GO:0032717 9.32 IL10 TLR9
13 positive regulation of toll-like receptor signaling pathway GO:0034123 9.26 TLR5 TLR9
14 immune system process GO:0002376 9.17 C4A C4B CR1 CTLA4 PTPN22 TLR5

Molecular functions related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.16 TLR5 TLR9
2 U2 snRNA binding GO:0030620 8.96 SNRPB TROVE2
3 IgG binding GO:0019864 8.8 FCGR2A FCGR2B FCGR3A

Sources for Systemic Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35